---
title: "Alzheimer’s Disease Models"
canonical: "https://www.pharmalegacy.com/indications/cns-disease-models/neurodegenerative-diseases/alzheimers-disease/"
lastmod: "2026-07-31T08:24:02+00:00"
generator: "llm-mirrors/1.0.19"
---

# PRECLINICAL STUDIES ON ALZHEIMER'S DISEASE
Get robust data on a wide range of Alzheimer’s pathophysiologies.

PHARMALEGACY HAS THE EXPERTISE AND MODELS YOU NEED TO ADVANCE YOUR ALZHEIMER’S DISEASE PROGRAM.

✕

Let PharmaLegacy provide the answers you need.

MODELS / SERVICES

5X FAD transgenic mouse model of Alzheimer’s Diseases ▼

Case Study - 5XFAD Transgenic Mouse Model & Endpoint Measurements

5X FAD Transgenic Mouse Model of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most prevalent age-related neurodegenerative disorder, pathologically characterized by amyloid plaque deposition, tau hyperphosphorylation and progressive neuronal loss in the brain. It leads to gradual impairment of learning, memory and executive function, ultimately resulting in severe dementia and loss of self-care ability.
In Alzheimer’s disease research, the 5XFAD transgenic mouse is one of the most widely applied animal models for recapitulating cerebral amyloid-β (Aβ) pathology and progressive cognitive deterioration. This model overexpresses human APP carrying three familial AD mutations together with mutant PSEN1 containing two pathogenic variants, triggering robust intracellular Aβ aggregation, extracellular amyloid plaque deposition, neuroinflammation, synaptic damage and gradual neuronal loss in the hippocampus and cerebral cortex, leading to typical AD-related learning and memory deficits. This transgenic strain is commonly adopted to dissect AD pathogenic mechanisms, test neuroprotective and anti-amyloid therapeutic strategies, and screen novel therapeutic candidates for Alzheimer’s disease. Among diverse transgenic AD models, the 5XFAD mouse is recognized as a preferred preclinical tool due to its early-onset, rapid pathological progression, excellent experimental reproducibility and high translational relevance to human amyloid pathology.
PharmaLegacy employs a series of behavioral tests including the Morris water maze, novel object recognition test and Y-maze test to evaluate whether test compounds alleviate learning and memory deficits in model animals. At the experimental endpoint, we perform systematic assessments combining histopathology, molecular biology and ex vivo electrophysiology, including quantitative analysis of amyloid plaque deposition, neuronal loss, synaptic integrity and neuroinflammation, Western blot and qPCR of Aβ-related proteins, inflammatory cytokines and synaptic markers, and ex vivo brain slice electrophysiology recording hippocampal long-term potentiation (LTP) and long-term depression (LTD).

Behavior – Anxiety & Depression (Open Field and Elevated Plus Maze Test)

Behavior – Morris Water Maze (MWM) Test

Electrophysiology – Long-Term Potentiation (LTP)

Golgi Staining – Dendritic Spine Density

Alzheimer-like dementia in cynomolgus monkey

Enforcing quality:

FDA Part 11 compliant
Rigorous adherence to international GLP and QA best practices
AAALAC accredited
1500+ validated animal models of disease spanning 100+ indications

Entrust your AD pipeline to a CRO with a standard of excellence. Entrust it to PharmaLegacy.

✕

Let PharmaLegacy provide the answers you need.

We’re ready when you are.             Tell us your AD pipeline challenges.

+86-21-6176-5100*8051
+1-617-803-9415

info@pharmalegacy.com

✕

Csv Download